Max Levin

3.2k citations
55 papers · 2.5k · 2 hit papers · h-index 25

Impact in

  • Oncology top 5%
    • Cancer Immunotherapy and Biomarkers
    • Cutaneous Melanoma Detection and Management
    • Lipid metabolism and biosynthesis

Papers in

    • Atherosclerosis and Cardiovascular Diseases 12
    • Cancer Immunotherapy and Biomarkers 8
    • Cutaneous Melanoma Detection and Management 3

Max Levin

55 papers receiving 2.4k citations

Max Levin's Hit Papers

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma 2021 · 137 citations
1370+1+3Years since publication100200300

Peers

Max Levin
Comparison fields: 5 of 94
  • Oncology 582
  • Biochemistry 111
  • Immunology 319
  • Cancer Research 156
  • Nephrology 107
Replace Tatsuhiko Miyazaki with:
Tatsuhiko Miyazaki Japan
Michelle N. Bradley United States
Honglei Weng Germany
Ke Ma China
Shirong Zhang China
Inés de Torres Spain
Claudio Celeghini Italy
Atsushi Umemura Japan
Yuanyuan Ruan China
Dae Young Hur South Korea
Max Levin relative to Tatsuhiko Miyazaki Japan Tatsuhiko Miyazaki's profile →
Citations per field
00.5×2×3.5×
Tatsuhiko Miyazaki · 1×
Citations per year

Countries citing papers authored by Max Levin

Since Specialization
Citations

This map shows the geographic impact of Max Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Levin more than expected).

Fields of papers citing papers by Max Levin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Levin. The network helps show where Max Levin may publish in the future.

Co-authors

The 25 scholars most cited alongside Max Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Max Levin Line = papers co-authored together Max Levin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Hit paper breakdown →
2021300
2 1999250
3 2016233
4 2013152
5
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Hit paper breakdown →
2021137
6 2020129
7 200989
8 200683
9 200065
10 200459
11 202159
12 201955
13 202255
14 201654
15 201251
16 201950
17 201242
18 200741
19 201941
20 201839

About Max Levin

Max Levin is a scholar working on Immunology, Oncology, Ophthalmology, Biochemistry and Molecular Biology, having authored 55 papers that have together received 2.5k indexed citations. Recurring topics across this work include Atherosclerosis and Cardiovascular Diseases (12 papers), Cancer Immunotherapy and Biomarkers (8 papers), Ocular Oncology and Treatments (5 papers), Cardiovascular Conditions and Treatments (3 papers), Lipid metabolism and biosynthesis (3 papers), Cutaneous Melanoma Detection and Management (3 papers), Cardiovascular Function and Risk Factors (3 papers) and Angiogenesis and VEGF in Cancer (3 papers). The work is most often cited by research in Oncology (582 citations), Biochemistry (111 citations), Immunology (319 citations), Cancer Research (156 citations) and Nephrology (107 citations). Max Levin has collaborated with scholars based in Sweden, United States and Norway. Frequent co-authors include Tom Björnheden, Olov Wiklund, Lillemor Mattsson Hultén, Jan Borén, Marcus Ståhlman, Lars Ny, Angelo Limeta, Jens Nielsen, Francesco Gatto and Boyang Ji. Their work appears in journals such as PLoS ONE, Arteriosclerosis Thrombosis and Vascular Biology, The Lancet Oncology, Atherosclerosis and Acta Oncologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact